Get the Stockscreener App
52.47
1.39%
-0.74
After Hours:
50.50
-1.97
-3.75%
Apogee Therapeutics Inc stock is traded at $52.47, with a volume of 1.83M.
It is down -1.39% in the last 24 hours and up +39.96% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$53.21
Open:
$53
24h Volume:
1.83M
Relative Volume:
2.83
Market Cap:
$2.42B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-19.05
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+31.57%
1M Performance:
+39.96%
6M Performance:
+75.25%
1Y Performance:
-2.67%
1-Day Range:
$51.06
$54.38
1-Week Range:
$39.21
$54.38
52-Week Range:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
52.47 | 3.17B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Will Apogee Therapeutics Inc. stock split attract more investorsAnalyst Upgrade & Smart Investment Allocation Insights - newser.com
Technical signs of recovery in Apogee Therapeutics Inc.Trade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
Apogee Therapeutics (NASDAQ:APGE) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Apogee Therapeutics closes $345 million public offering By Investing.com - Investing.com Nigeria
Apogee Therapeutics Raises $345 Million From Public Offering - MarketScreener
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - GlobeNewswire
$345M Raised — Apogee Therapeutics Closes Offering of 8.05M Shares Including Pre-Funded Warrants - Stock Titan
Best Biotech Stocks To ConsiderOctober 9th - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Given "Buy" Rating at BTIG Research - MarketBeat
What’s the recovery path for long term holders of Apogee Therapeutics Inc.Swing Trade & Weekly High Conviction Ideas - newser.com
Does Apogee Therapeutics' (APGE) $300 Million Raise Mark a Shift in Its R&D Ambition? - Yahoo Finance
Apogee Therapeutics raises $323.3 million in public offering on Nasdaq By Investing.com - Investing.com Canada
Apogee Therapeutics raises $323.3 million in public offering on Nasdaq - Investing.com India
Apogee Therapeutics Raises $323.3 Million in Offering - TipRanks
Published on: 2025-10-10 05:23:46 - newser.com
Form 424B5 Apogee Therapeutics, - StreetInsider
Reversal indicators forming on Apogee Therapeutics Inc. stockQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Apogee Therapeutics' (APGE) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Why Apogee Therapeutics Stock Triumphed on Thursday - The Globe and Mail
Why Apogee Therapeutics Stock Triumphed on Thursday - The Motley Fool
Delta Air Lines, Costco rise premarket; Apogee Therapeutics slips - Investing.com
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today - Stocktwits
Delta Air Lines, Costco rise premarket; Apogee Therapeutics slips By Investing.com - Investing.com Australia
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Biggest stock movers Thursday: TLRY, AKRO, DAL, and more (APGE:NASDAQ) - Seeking Alpha
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Published on: 2025-10-09 03:41:55 - newser.com
Apogee Therapeutics prices $300 million public offering By Investing.com - Investing.com Australia
Apogee Therapeutics prices $300 million public offering - Investing.com
Apogee Therapeutics, Inc. announces pricing of $300 million underwritten public offering - MarketScreener
$300M Offering: Apogee Therapeutics Prices 6.95M Shares; Includes Pre-funded Warrants Exercisable Immediately - Stock Titan
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire
Apogee Therapeutics launches common stock public offering By Investing.com - Investing.com Nigeria
Apogee Therapeutics announces proposed underwritten public offering - MarketScreener
Apogee Therapeutics stock falls after announcing proposed public offering By Investing.com - Investing.com Canada
Apogee Therapeutics Launches Public Offering - MarketScreener
Apogee Therapeutics drops on stock offering launch - TradingView
Apogee Therapeutics launches common stock public offering - Investing.com
Apogee Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering - GlobeNewswire
15% Overallotment Option — Apogee Therapeutics Commences Public Offering to Fund Trials - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) Trading Up 6.9%Here's What Happened - MarketBeat
Published on: 2025-10-05 04:04:42 - newser.com
What analysts say about Apogee Therapeutics Inc stockStock Split Announcements & In-Depth Analyst Ratings Explained Simply - earlytimes.in
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,110 Shares - MarketBeat
Can RBC's Optimism Reveal the Competitive Edge Behind Apogee Therapeutics' (APGE) Immunology Pipeline? - simplywall.st
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89 - 富途牛牛
What indicators show strength in Apogee Therapeutics Inc.July 2025 Sector Moves & Safe Swing Trade Setups - newser.com
How to recover losses in Apogee Therapeutics Inc. stockJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
Apogee Therapeutics Inc. $APGE Stock Position Decreased by Platinum Investment Management Ltd. - MarketBeat
Published on: 2025-10-01 05:00:38 - newser.com
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apogee Therapeutics Inc Stock (APGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Oct 01 '25 |
Sale |
39.80 |
5,110 |
203,378 |
284,733 |
| Dambkowski Carl | Chief Medical Officer |
Sep 03 '25 |
Sale |
37.87 |
2,725 |
103,198 |
233,548 |
| Dambkowski Carl | Chief Medical Officer |
Aug 06 '25 |
Sale |
37.78 |
2,725 |
102,950 |
236,273 |
| Dambkowski Carl | Chief Medical Officer |
Jul 02 '25 |
Option Exercise |
22.86 |
7,365 |
168,364 |
249,088 |
| Dambkowski Carl | Chief Medical Officer |
Jul 02 '25 |
Sale |
45.09 |
10,090 |
454,954 |
238,998 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):